• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Esteve Pharmaceuticals to market Inbrija levodopa DPI in Spain

Esteve Pharmaceuticals has acquired the exclusive rights to market Inbrija dry powder levodopa in Spain and expects to launch the product there by the end of 2022, according to Acorda Therapeutics. Esteve will pay Acorda “a significant double-digit percent of the selling price” for Acorda to supply the product.

The Inbrija DPI was approved in Europe for the treatment of OFF periods in Parkinson’s disease in 2019. In the US, the FDA approved Inbrija in December 2018, and Acorda launched the DPI in February 2019. In January 2021, Acorda sold the Inbrija manufacturing facility in Massachusetts to Catalent, with Catalent taking over production of the inhaled levodopa.

Acorda President and CEO Ron Cohen commented, “We are delighted to enter a partnership with Esteve to make Inbrija available in Spain. This is great news for people with Parkinson’s in Spain who are in need of therapies to treat their OFF periods. Esteve has an impressive track record of successfully commercializing pharmaceuticals in Europe for neurological and other indications. We are also in active discussions with additional companies for the rights to Inbrija in other countries in Europe and the rest of the world.”

Read the Acorda Therapeutics press release.

Share

published on July 22, 2021

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews